Insight, China's Pharmaceutical Industry

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow...

Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Fineline Cube May 20, 2026

Bayer AG (ETR: BAYN) announced today that the U.S. Food and Drug Administration (FDA) has...

Others

UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis

Fineline Cube May 20, 2026

UCB (EBR: UCB) announced today Week 16 data from the BE BOLD Phase III clinical...

Company Drug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

Fineline Cube May 20, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from...

Company Drug

ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus

Fineline Cube May 20, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient...

Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Fineline Cube May 19, 2026

Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and...

Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Fineline Cube May 19, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) has restructured its vaccine business operations in China, splitting the...

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026

Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34%...

Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company...

Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Fineline Cube May 19, 2026

Lundbeck (OTCMKTS: HLUBF) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...

Company Drug

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

Fineline Cube May 19, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China...

Company Drug

CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor

Fineline Cube May 19, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China’s...

Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover...

Company Drug

Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis

Fineline Cube May 19, 2026

Boehringer Ingelheim (BI) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...

Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Fineline Cube May 19, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026

Zhejiang Shimai Pharmaceutical Co., Ltd., a T-cell engager (TCE) specialist founded in 2017, has filed...

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026

Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China,...

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026

Youcare Pharmaceutical Group (SHA: 688658) announced a RMB 1 billion ($147 million) investment to establish...

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301...

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026

BrightGene (Suzhou) Bio-Medical Technology Co., Ltd. (SHA: 688166) has filed its prospectus with the Hong...

Insight, China's Pharmaceutical Industry

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

You Missed

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results